These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 35925450

  • 1. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
    [Abstract] [Full Text] [Related]

  • 2. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Aso S, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
    [Abstract] [Full Text] [Related]

  • 3. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
    Suzuki T, Michihata N, Hashimoto Y, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2024 Jan; 183(1):415-424. PubMed ID: 37917176
    [Abstract] [Full Text] [Related]

  • 4. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 5. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T, Michihata N, Yoshikawa T, Hata T, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2020 Dec 01; 179(12):1901-1907. PubMed ID: 32862279
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 01; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 7. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Int J Rheum Dis; 2022 May 01; 25(5):576-583. PubMed ID: 35258165
    [Abstract] [Full Text] [Related]

  • 8. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
    Cardiovasc Ther; 2021 May 01; 2021():6660407. PubMed ID: 34239607
    [Abstract] [Full Text] [Related]

  • 9. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J, Su D, Yuan P, Ye B, Qin S, Pang Y.
    Cardiology; 2023 May 01; 148(5):457-468. PubMed ID: 37231847
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 01; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 11. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
    Clin Rheumatol; 2020 Dec 01; 39(12):3747-3755. PubMed ID: 32458247
    [Abstract] [Full Text] [Related]

  • 12. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A, Inoue M, Hoshina T, Koga H.
    J Pediatr; 2021 Sep 01; 236():95-100. PubMed ID: 34019881
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 14. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 01; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 01; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 16. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
    Arch Dis Child; 2023 Oct 01; 108(10):833-838. PubMed ID: 37258054
    [Abstract] [Full Text] [Related]

  • 17. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 01; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 18. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 19. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 31; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.